JOP20200294A1 - مشتقات ثنائي هيدروبيرازولو بيرازين كربوكساميد تحمل بدائل - Google Patents

مشتقات ثنائي هيدروبيرازولو بيرازين كربوكساميد تحمل بدائل

Info

Publication number
JOP20200294A1
JOP20200294A1 JOP/2020/0294A JOP20200294A JOP20200294A1 JO P20200294 A1 JOP20200294 A1 JO P20200294A1 JO P20200294 A JOP20200294 A JO P20200294A JO P20200294 A1 JOP20200294 A1 JO P20200294A1
Authority
JO
Jordan
Prior art keywords
dihydropyrazolo
substituted
carboxamide derivatives
pyrazine carboxamide
disorders
Prior art date
Application number
JOP/2020/0294A
Other languages
English (en)
Inventor
Helmut Michael Ehrmann Alexander
Buchmuller Anja
Kersten Elisabeth
Jimenez Nunez Eloisa
Schmidt Georg
Muller Steffen
Gerisch Michael
Timmermann Andreas
Pook Elisabeth
Lang Dieter
Wang Vivian
Wang Yafeng
Schohe-Loop Rudolf
Gao Xiang
Sussmeier Frank
Gerdes Christoph
Lehmann Lutz
Lindner Niels
Brumby Thomas
Schlemmer Karl-Heinz
Ortega Hernandez Nuria
Zdenka Gaugaz Fabienne
SCH?FER Martina
Follmann Markus
Zimmermann Stefanie
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of JOP20200294A1 publication Critical patent/JOP20200294A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق هذا الاختراع بمشتقات ثنائي هيدروبيرازولو بيرازين كربوكساميد تحمل بدائل وعمليات لتحضيرها، كما يتعلق أيضاً باستخدامها لتحضير أدوية لمعالجة و/أو الوقاية من الأمراض، وبالتحديد إضطرابات قلبية وعائية، والأفضل إضطرابات خُثارية أو انصمامية خثارية، وداء السكري، بالإضافة إلى إضطرابات بولية تناسلية وإضطرابات عينية
JOP/2020/0294A 2018-05-17 2019-05-10 مشتقات ثنائي هيدروبيرازولو بيرازين كربوكساميد تحمل بدائل JOP20200294A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018087249 2018-05-17
PCT/EP2019/062005 WO2019219517A1 (en) 2018-05-17 2019-05-10 Substituted dihydropyrazolo pyrazine carboxamide derivatives

Publications (1)

Publication Number Publication Date
JOP20200294A1 true JOP20200294A1 (ar) 2020-11-17

Family

ID=66625151

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0294A JOP20200294A1 (ar) 2018-05-17 2019-05-10 مشتقات ثنائي هيدروبيرازولو بيرازين كربوكساميد تحمل بدائل

Country Status (25)

Country Link
US (1) US20220324865A1 (ar)
EP (1) EP3793559A1 (ar)
JP (1) JP2021523910A (ar)
KR (1) KR20210013084A (ar)
CN (1) CN112469412A (ar)
AR (1) AR114906A1 (ar)
AU (1) AU2019270142A1 (ar)
BR (1) BR112020021612A2 (ar)
CA (1) CA3100221A1 (ar)
CL (1) CL2020002974A1 (ar)
CO (1) CO2020014201A2 (ar)
CR (1) CR20200554A (ar)
CU (1) CU20200084A7 (ar)
EA (1) EA202092779A1 (ar)
EC (1) ECSP20072258A (ar)
JO (1) JOP20200294A1 (ar)
MA (1) MA52623A (ar)
MX (1) MX2020012201A (ar)
NI (1) NI202000083A (ar)
PE (1) PE20210856A1 (ar)
PH (1) PH12020551973A1 (ar)
SG (1) SG11202010679SA (ar)
TW (1) TW202012408A (ar)
UY (1) UY38237A (ar)
WO (1) WO2019219517A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018049152A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MA46191A (fr) 2016-09-09 2021-04-21 Incyte Corp Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
AU2020326703A1 (en) 2019-08-06 2022-02-17 Incyte Corporation Solid forms of an HPK1 inhibitor
WO2021094208A1 (en) * 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
WO2021094210A1 (en) * 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
CN114236017B (zh) * 2022-02-23 2022-06-07 深圳市海滨制药有限公司 一种棕榈酸抗坏血酸酯及其杂质的检测方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2005251820A1 (en) 2004-06-09 2005-12-22 Merck & Co., Inc. HIV integrase inhibitors
DE102004054665A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
DE102007032349A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
CN101945875B (zh) 2007-12-21 2013-04-24 健泰科生物技术公司 氮杂吲嗪及其使用方法
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
NZ602018A (en) 2010-02-27 2014-10-31 Bayer Ip Gmbh Bisaryl-bonded aryltriazolones and use thereof
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2708539A1 (de) 2010-07-09 2014-03-19 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
PT2831077T (pt) * 2012-03-28 2016-08-12 Merck Patent Gmbh Derivados bicíclicos pirazinona
WO2014139326A1 (en) 2013-03-13 2014-09-18 Genentech, Inc. Pyrazolo compounds and uses thereof
ES2665153T3 (es) * 2013-10-09 2018-04-24 Pfizer Inc. Antagonistas del receptor EP3 de prostaglandina
WO2015063093A1 (de) * 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3112369A4 (en) 2014-02-27 2017-09-20 The University of Tokyo Fused pyrazole derivative having autotaxin inhibitory activity
MX2017005479A (es) 2014-11-03 2017-07-04 Bayer Pharma AG Derivados de feniltriazol sustituido con hidroxialquilo y sus usos.
EP3237401B1 (en) 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor
PT3419978T (pt) 2016-02-24 2020-06-01 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inibidores de jak

Also Published As

Publication number Publication date
MX2020012201A (es) 2021-01-29
NI202000083A (es) 2021-03-11
CL2020002974A1 (es) 2021-03-05
PH12020551973A1 (en) 2021-08-02
CU20200084A7 (es) 2021-06-08
AU2019270142A1 (en) 2020-11-12
UY38237A (es) 2019-11-29
ECSP20072258A (es) 2020-12-31
SG11202010679SA (en) 2020-11-27
BR112020021612A2 (pt) 2021-01-26
US20220324865A1 (en) 2022-10-13
TW202012408A (zh) 2020-04-01
CR20200554A (es) 2021-01-12
PE20210856A1 (es) 2021-05-18
CO2020014201A2 (es) 2021-03-08
EA202092779A1 (ru) 2021-02-02
EP3793559A1 (en) 2021-03-24
WO2019219517A1 (en) 2019-11-21
MA52623A (fr) 2021-03-24
AR114906A1 (es) 2020-10-28
CA3100221A1 (en) 2019-11-21
CN112469412A (zh) 2021-03-09
JP2021523910A (ja) 2021-09-09
KR20210013084A (ko) 2021-02-03

Similar Documents

Publication Publication Date Title
JOP20200294A1 (ar) مشتقات ثنائي هيدروبيرازولو بيرازين كربوكساميد تحمل بدائل
JO3703B1 (ar) مشتقات أوكسوبيريدين مستبدلة
TN2015000434A1 (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
CR20210342A (es) Derivados de oxopiridina sustituidos
PH12015500988A1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
PH12016500065A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
TN2015000370A1 (en) Trifluormethyl-substituted ring-fused pyrimidines and use thereof
EA201891374A1 (ru) Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение
JOP20200073A1 (ar) مركبات أميد إيميدازوبيريدين تحمل بدائل واستخداماتها
JOP20170113B1 (ar) مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها
TN2009000503A1 (en) Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation
EP4364805A3 (en) Novel pyridazines
PH12016500608A1 (en) Cyclic thienouracil-carboxamides and use thereof
WO2015165933A3 (de) Imidazo[1,2-a]pyridine als stimulatoren der löslichen guanylatcyclase zur behandlung von kardiovaskulären erkrankungen
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
MX2009013709A (es) (oxazolidinon-5-ilmetil)-2-tiofenocarboxamidas sustituidas y su uso en el campo de la coagulación sanguínea.
CR20240114A (es) Derivados de s–alaninato sustituidos
MX2020006641A (es) Proceso para la preparacion de compuestos de pirimidinil-4-aminopi razol.
TW200635920A (en) Pyrazinedicarboxamides and their use
TN2015000523A1 (en) Substituted benzoxazoles